Home Page : www.otcjournal.com
Email Questions or Comments To:
editor@otcjournal.com
To
OTC Journal Members:
 |
Important
Notice: |
 |
I am becoming more enamored with
the idea of looking for dividend situations in the microcap world. The
Bad Toys spin off of Southland Health Services- albeit taking
a long time- looks very promising. There is a lot going on behind the scenes-
it is all adding up to a strong comfort level that Southland has
a real shot of opening for trading on the NASDAQ.
In addition, revenue monster Titan
Global is spinning out their printed circuit board division into a
separate publicly traded company- when the time comes every shareholder
will participate in that dividend spin out as well.
I've identified a third dividend
situation as well- a very unique situation wherein shareholders will receive
free trading shares in other publicly traded companies. This one is growing
like a weed in spring. Stand by for more information later this week.
 |
eFoodSafety:
Cinnergen Distribution Blazing Trail For Other Products |
|
This past November eFoodsafety
made a directional change on the product you see pictured here. Until that
point, EFSF only had the rights to market the Cinnergen.
The company decided to stop the direct marketing campaign for the product,
and sell it through retail outlets. In conjunction, they bought the product
in its entirety from the developer (Nutralab) for $1.3 million, and paid
the majority of the cost in stock.
Since making the transition, Cinnergen
is now marketed through approximately 7,200 retail stores,
and the company believes that number could approach 20,000 by the
end of June, with a lot more high profile retailers signing on. When you
consider the short time frame, it's a remarkable achievement.
There have been some major changes
in the product's value. Personally, I believe the most important major
change was the publication of a clinical study proving Cinnergen
reduces blood glucose levels and helps your body metabolize sugar. In the
world of low carb diets and the raging epidemic of Type II diabetes, this
is a major breakthrough. Retailers want to carry the product now that its
efficacy has been established.
In my view, making the move from
a direct marketing company to a wholesale supplier opens doors on multiple
fronts. EFSF is not only going to end up with far more effective
distribution of Cinnergen, it is also blazing the distribution trail
for future retail products the company is working on right now.
First will be Cinnechol(TM)-
their natural product developed to reduce cholesterol- both total cholesterol
and the hdl/ldl ratio, with is good cholesterol vs bad cholesterol. Cinnechol(TM)
will follow the same template the company is pursuing with Cinnergen.
A distribution relationship with
20,000 retailers has immense intangible value- especially if you can leverage
that relationship with other products. Cinnergen is currently gaining
momentum with retailers. Cinnechol(TM) will be introduced to the
same network in the near future, and there is now a third product to follow.
Today, just as the market opened,
EFSF
announced it will be introducing Citroxin O2- a chewable cold remedy,
to its retail distribution network. According to the press release, the
"Citroxin O2 formula will contain Zinc, several vital electrolytes,
vitamin C and immune enhancing probiotics. As a lozenge, the unique benefits
of Citroxin O2 and synergistic ingredients will begin working immediately
in the membranes of the sinuses and oral cavity to help reduce both the
severity and duration of the cold virus."
As with Cinnergen and Cinnechol,
EFSF plans to start a clinical trial within two months. My guess- they
hope to take the product to market for next Fall to Spring's cold season.
Here's what I see happening for the
remainder of 2007. EFSF will demonstrate sales traction on Cinnergen-
and with more retail chains. Revenues will start increasing very dramatically
in successive quarters.
The Dupont relationship for
Oraphyte
is a wild card as well. If the company inks a distribution agreement with
Dupont, all bets are off to the upside. That product could dwarf the
potential of Cinnergen, Cinnechol, and Citroxin combined.
In the meantime, as measured from
the late February move from the mid $.30 range, EFSF is now
camped at the absolutely perfect level to accumulate the stock right now.
The next volume surge on some piece
of big news could take the stock through the long term downtrend line and
set a new precedent for higher levels.
Accumulate right now at $.415
- SSL: $.36.
Here is the complete text of today's
news for your review:
| Press Release Source:
eFoodSafety.com, Inc.
eFoodSafety.com, Inc.
Formulates All-Natural Cold Remedy
Monday March 26, 9:30
am ET
Company Takes Aim at the Common
Cold Costing U.S. Economy $40B with Introduction of All-Natural Chewable
Lozenge Featuring Citroxin O2
SCOTTSDALE, Ariz.--(BUSINESS
WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF - News), a Company dedicated
to improving health conditions around the world through innovative products
and technologies, today announced that it has formulated a novel all-natural
cold remedy in the form of a chewable lozenge featuring Citroxin O2. Citroxin
O2 is an all-food grade formula, containing no chemicals or pharmaceuticals.
It has been proven one hundred percent effective in vitro by independent
laboratory testing against many pathogens, including: Staph Aureus, Streptococcus
Pneumoniae, and Pseudomonas Aeruginosa. Citroxin O2 has proven anti-viral
capability, a vital necessity as 200 different known viruses can cause
the common cold.
This Citroxin O2 formula
will contain Zinc, several vital electrolytes, vitamin C and immune enhancing
probiotics. As a lozenge, the unique benefits of Citroxin O2 and synergistic
ingredients will begin working immediately in the membranes of the sinuses
and oral cavity to help reduce both the severity and duration of the cold
virus.
The common cold with
its nagging and oftentimes severe symptoms is pervasive in society. Every
year, the U.S. population experiences up to one billion colds. Although
colds can happen anytime, they occur most often in the winter and spring.
Annually, approximately 189 million school days are lost to colds with
another 126 million days of work lost for at least one parent to stay home
to tend to their sick child. Up to the age of 17, the number of colds caught
per year is 5-12. People above the age of 18 catch 2-4 colds per year.
The economic impact of
the common cold is staggering. Studies have shown that in the U.S. on a
yearly basis, $2.9 billion is spent on OTC cold remedies, $400 million
on prescriptions, and another $1.1 billion on anti-biotic prescriptions
to treat secondary bacterial infections due to colds. Approximately 100
million visits are paid to the doctor each year from contracting a cold,
resulting in a cost of about $7.7 billion. All told, it is estimated that
the annual cost to the U.S. economy from the common cold equals about $40
billion each year.
Patricia Gruden, President
and CEO of eFoodSafety.com, Inc. stated, "We're pleased to introduce this
new product to our expanding and evolving list of better health related
offerings. We anticipate commencing clinical trials on this product within
the next 60 days."
Gruden further commented,
"It's an exciting time here at eFoodsafety.com as evidenced by many of
our announcements of recent months. Having now established a strong distribution
channel for Cinnergen(TM) including some of the top retailers in the world,
we believe the potential for cross-selling opportunities is high. We have
established a strong foundation allowing us to leverage future growth and
we are now seeing tangible results in the form of increasing sales. We
anticipate reporting the increasing revenues in forthcoming quarters having
already experienced the typical 60-90 day lag time from initial sale to
collection of the receivable allowing us to physically book the revenues."
About eFoodSafety.com,
Inc.
eFoodSafety.com, Inc.
is dedicated to improving health conditions around the world through its
innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary
has developed an environmentally safe sporicidal product formulated entirely
of food-grade components that eradicates anthrax and a germicidal product,
Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills
six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus,
and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product
has completed its final efficacy laboratory study requisite for EPA registration.
In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis
with 100% efficacy on both hard and porous surfaces. The company's MedElite,
Inc. subsidiary distributes clinically proven products to physicians who
then prescribe the products for their patients. It recently became the
owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven
to facilitate and improve the appearance, redness and strength of scars
(www.talsyn.com), as well as seven (7) other products in the Talsyn(TM)
line. The Company is also owner of Cinnergen(TM), a clinically-studied,
non-prescription liquid whole food nutritional supplement that promotes
healthy glucose metabolism (www.cinnergen.com) and Cinnechol(TM), a new
multi-faceted nutritional supplement specifically designed to naturally
reduce total cholesterol levels without causing any side effects. The Company
has entered into a joint venture agreement with CK41 Direct, Inc. to launch
the PurEffect(TM) anti-acne skin care system.
Please visit the Company's
website at: http://www.efoodsafety.com.
Safe Harbor Forward-Looking
Statements
Statements contained
in this release that are not strictly historical are "forward-looking"
statements within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934.. The forward-looking
statements are made based on information available as of the date hereof,
and the Company assumes no obligation to update such forward-looking statements.
Editors and investors are cautioned that such forward-looking statements
involve risks and uncertainties that could cause the Company's actual results
to differ materially from those in these forward-looking statements. Such
risks and uncertainties include but are not limited to demand for the Company's
products and services, our ability to continue to develop markets, general
economic conditions, our ability to secure additional financing for the
Company and other factors that may be more fully described in reports to
shareholders and periodic filings with the Securities and Exchange Commission.
Contact:
Redwood Consultants,
LLC
Jens Dalsgaard, 415-884-0348
Source: eFoodSafety.com,
Inc. |
|
